The global sales of platelet rich plasma is estimated to be worth USD 444.4 million in 2024 and anticipated to reach a value of USD 1,163.1 million by 2034. Sales are projected to rise at a CAGR of 10.1% over the forecast period between 2024 to 2034. The revenue generated by platelet rich plasma cover in 2023 was USD 403.6 million. The industry is anticipated to exhibit a Y-o-Y growth of 10.1% in 2024.
Platelet-rich plasma is an autologous substance that is extracted through centrifugation of the patient's blood, separating the plasma from platelets and growth-factor from the rest of the blood components. These growth factors are key elements in the regeneration of PRP, which plays a pivotal role in amplifying natural growth towards tissue repair, new blood vessels development etc.
These platelet rich plasma are widely used in orthopedics indications which can accelerate the recovery of injuries in ligaments as well as tendons and are also used for symptomatic management of osteoarthritis.
The use of PRP in dermatology and aesthetics has been phenomenal with many improved applications such as skin rejuvenation, wrinkle treatment, scarring, and is conducive to hair growth in conditions such as androgenetic alopecia. They are also used for regeneration of bones in dental surgery and added enhanced rate of wound healing in chronic wound care.
Global Platelet Rich Plasma Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 403.6 million |
| Estimated Size, 2024 | USD 444.4 million |
| Projected Size, 2034 | USD 1,163.1 million |
| Value-based CAGR (2024 to 2034) | 10.1% |
Platelet-rich plasma plays an important role in treating a wide range of indications and has been found highly effective in treatment of dermatology indication as well as wound care. It is being applied in orthopedics to treat tendonitis and osteoarthritis.
PRP has several application in dermatology where dermatologists apply PRP for skin rejuvenation and hair restoration. It is also used in dentistry by the dentists for enhancing the process of bone healing after oral surgical procedures. It also finds its application in wound healing cases of chronic ulcers. In recent years, platelet-rich-plasma is finding its major use in cosmeceutical industry as they aid in expediting recovery after cosmetic surgeries. Its increase in use is due to the low-risk associated with the augmentation of repair and regeneration of various tissue specialties with improved patient outcomes.
The platelet rich plasma cover market is set to experience a significant growth of 10.1% during the forecast period. It is projected to create an incremental opportunity of USD 718.7 million and is predicted to rise 2.6 times the current market value through 2034.
Rising prevalence of orthopedic conditions among ageing population, and the increasing number of dental problems among younger population is significantly contributing to the growth of the platelet-rich plasma market. These treatment is also gaining traction in sports injuries as it effectively stimulate tissue repair and healing for joint injuries.
Moreover, limited risk of adverse reaction owing to its autologous origin enforces the safety, of the patients. Therefore, increased patient and health care provide awareness and technological advancements in the preparation and application of PRP, across different medical specialties, promising better outcomes and recovery for patients are some of the factors augmenting the growth of the market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table below compares the Compound Annual Growth Rate (CAGR) for the global platelet rich plasma market from 2023 to 2024 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics. H1 covers January to June, while H2 spans July to December.
| Particular | Value CAGR |
|---|---|
| H1 | 11.4% (2023 to 2033) |
| H2 | 10.8% (2023 to 2033) |
| H1 | 10.1% (2024 to 2034) |
| H2 | 9.8% (2024 to 2034) |
In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 11.4%, followed by a slightly decline in growth rate of 10.8% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to increase slightly to 10.1% in the first half and remain relatively moderate at 9.8% in the second half. In the first half (H1) the market witnessed a decrease of 130 BPS while in the second half (H2), the market witnessed a decrease of 100 BPS.
Growing Application of Platelet Rich Plasma in Healthcare Industry is Augmenting its Market Growth
PRP is a concentrated mixture of platelets, growth factors, and cytokines that derive from the patient's own blood. The importance of PRP is increasing in the medicinal field owing to its results related to regeneration and its diverse scope of applications such as osteoarthritis, tendonitis, and ligament injuries.
Platelet rich plasma is an autologous blood product that provides patients and the healthcare provider with successful therapies. They have limited side effects which is one of the major factors for its increased growth in the market. In general, the minimal invasiveness and excellent safety profile of PRP makes it an autologous blood product which helps healthcare provider to carry out successful therapies.
PRP is also witnessing rising clinical evidence through various research studies which states that they assists in wound healing and provides patients with more improved surgical outcomes. These are few of the factors that have significantly contributed its acceptance among healthcare professionals.
Platelet rich plasma also finds its application in dermatology field where it is used for restoration of hair, skin rejuvenation, and scar reduction. It also stimulates collagen production and tissue repair. Therefore, the ability of the platelet-rich plasma to heal using the natural process of the body majorly contributes to its expanding applications in the medicinal industry which surges its further growth in the exponentially growing healthcare industry.
Growing Adoption of Platelet Rich Plasma in Cosmetic Industry Owing to its Advantages
Platelet rich plasma is gaining fast traction among cosmetic professionals owing to its natural approach towards skin rejuvenation and hair restoration. Its increased use as growth factors and its added advantages which aids in improved collagen production significantly contributes to its increased use in cosmetic industry.
In addition to this, its other advantages such as its ability to provide enhanced skin texture, assistance in demonstrating a reduced fine lines, and wrinkles in individuals skin contributes to its significant adoption among population who are extremely focused towards their aesthetic appearance.
Additionally, the reduced risk profile of platelet rich plasma, due to its minimal invasiveness makes it an excellent attraction among patients who are seeking to undergo nonsurgical procedures. It offers very negligible recovery time as compared to the time which is required for conventional cosmetic procedures.
Studies and positive reviews of PRP has further validated the effectiveness of these treatments, which has significantly fueled its demand in the cosmetic industry. Moreover, cosmetic clinics and dermatologists are also introducing this therapies as one of their offerings, which has significantly improved its accessibility in the market.
The fact that PRP is driven by a natural regenerative property, non-invasiveness, and growing availability in aesthetic practices, has led to this innovation which has made it one of the most in-demand procedures for skin rejuvenation and hair rejuvenation.
Rising Prevalence of Orthopedic Diseases Brings New Business Opportunities for the PRP Providers
Rising incidence of orthopedic indications such as osteoarthritis, ligament strains and injuries related to tendons is significantly contributing to the growth of the PRP market. This rising incidence are majorly attributed to various factors such as aging populations and increased participation young adults in sporting and physical activities. For instance, according to an article published by National Library of Medicine in April 2024, a total number of 1,389 cases of anterior cruciate ligament injury were reported in female athletes playing soccer.
Platelet rich plasma has emerged as a non-surgical, regenerative process for patients seeking treatment beyond what traditional therapy or surgery has to offer. This increased demand means an increase in prescriptions for PRP injections and treatments from orthopedic clinics and sports medicine practices for the PRP provider.
Inclusion of PRP therapy in an individual’s orthopedic practice provides them with an enlarged scope, as it helps them to serve large number of patient population seeking for orthopedic care.
With the current upward trend of orthopedic diseases, the landscape is very fertile for new ideas from PRP providers, inclusion of PRP therapy in their daily patient care practice can aid them to establish themselves as thought leaders in regenerative medicine which can aid them in expanding their market presence in the modern orthopedic care.
Growing Research and Development Activities in the Field of Platelet Rich Plasma
Owing to its huge potential across diverse medical and therapeutic applications, platelet rich plasma has entered into a renovated phase of growth in research and development. Scientists are actively pursuing new avenues beyond the established uses in orthopedics and dermatology.
Researchers are constantly emphasizing on the study of molecular mechanisms by which PRP forms its therapeutic effects. They are making efforts to understand the detailing on how it activates cellular processes like angiogenesis and collagen synthesis.
They are also focusing on the development of treatment for chronic wounds, cardiovascular diseases, and dental procedures throygh PRP. Clinical trials are included for establishing the safety and efficacy of PRP across medical disciplines, facilitating its adoption into clinical practice.
A number of regulatory initiatives are currently underway with regard to the standardization of PRP methodologies for the sake of consistency in preparation and application as it act as a versatile tool for regenerative medicine, making it one of the suitable and available treatment options for various diseases.
Therefore, the increasing investment in research and development activities for studying the potential effect of PRP contributes to its market growth.
Principal Consultant
The global platelet rich plasma cover industry recorded a CAGR of 8.6% during the historical period between 2019 and 2023. The growth of platelet rich plasma cover industry was positive as it reached a value of USD 403.6 million in 2023 from 257.4 million in 2019.
Increasing applications of medical technology in orthopedics and dermatology have significantly driven the sales growth of platelet rich plasma. Preferential shift of patients towards non-surgical treatment method; growing awareness among health professionals for its regenerative properties, have significantly contributed to its increased demand in the market.
In addition, this therapy has also witnessed a significant adoption rate among ageing population suffering from chronic disorders. These are few of the pivotal reasons support the future growth of platelet-rich plasma.
Growing research and clinical evaluation for new indications, such as cardiovascular diseases and chronic wounds, will increase its utility and market. As populations become older throughout the world, demand for non-surgical and regenerative treatments like PRP will rise in a way to address age-related degenerative conditions more effectively.
The preference by patients for therapies that are not invasive in nature further fuels the interest in PRP as it offers, a much safer and faster recovery in comparison to traditional surgery methods. Further, celebrity and athlete endorsements, owing to very strong clinical evidence of its effectiveness, adds more credibility to PRP and boosts its sales in the medical community.
In addition, the evolving regulatory frameworks aimed at supporting this new frontier of medicine, which ensures its safe in standardized manner further augments its growth among healthcare fraternity. These factors all point to a great future for PRP, which places it at the forefront of regenerative medicine and healthcare.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 15% to 20% in global market. These market leaders are characterized by high production capacity, wide product portfolio, and range of services in the market.
These market leaders are differentiating themselves from the market based on the technology, extensive expertise in manufacturing and broad geographical outreach reach in the market. These factors have aided them in serving a wide range of consumer base. Prominent companies within tier 1 include Harvest Technologies Corp., Johnson & Johnson Services, Inc., Stryker, Zimmer Biomet Holdings Inc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions with their high influence on the local market. These are characterized by a strong presence overseas and strong market knowledge. These market players have good technology and ensure regulatory compliance but may be limited to their availability in certain markets. Prominent companies in tier 2 include Arthrex, Inc., Arteriocyte Medical Systems, Inc., Dr. PRP America, Cesca Therapeutics, Inc.
Tier 3 includes the majority of companies that have limited geographical outreach or are operating at the local presence and serving niche markets having revenue below USD 50 million. These companies are focused towards fulfilling the demand from local market and are therefore classified as the tier 3 share segment. They are comparatively small-scale players and are recognized as an unorganized market, which doesn’t have extensive infrastructure structure or higher production capabilities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the platelet rich plasma cover market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, and is projected to grow at a CAGR of 3.1% through 2034. In Asia Pacific, India is projected to witness a CAGR of 11.4% by 2034.
| Country | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 5.5% |
| Spain | 5.9% |
| France | 5.1% |
| South Korea | 8% |
| China | 10.1% |
| Australia | 4.6% |
Germany’s platelet rich plasma cover market is poised to exhibit a CAGR of 3.1% between 2024 to 2034. Growth in the platelet-rich plasma market in Germany is driven by advanced healthcare infrastructure, increased expenditure on healthcare supporting innovative treatments, and an aging population. The growing trend among patients to prefer non-surgical alternatives as a treatment for their orthopedic conditions such as osteoarthritis and in dermatological application falls further supports its growth in the country. Moreover, rising incidence of musculoskeletal disorders among ageing population, and increase in number of sports injuries in young athletes further drives the market growth.
In addition, rise in clinical evidence and product acceptance provided by health care professionals further bolsters PRP's adoption in the Germany. The combination of these factors continues to foster a growing PRP market in Germany which may aid it to establish as a prime leader in regenerative medicine.
North America, spearheaded by the USA currently holds majority of the share of the global platelet rich plasma cover industry. The market in the USA is anticipated to grow at a CAGR of 3.1% throughout the forecast period 2034.
The PRP market in the USA is projected to grow at a significant growth rate owing to the rising prevalence of orthopedic cases in the country. For instance, according to an article published by Osteoarthritis (OA) Action Alliance in May 2020, osteoarthritis (OA) is the most common form of arthritis. It has affected around 32.5 million of the people in the USA Moreover, the availability of advanced healthcare facilities across specialties such as orthopedics and dermatology with proactive reimbursement policies further augments the growth of the market.
In addition, extensive ongoing clinical research towards validation of the effectiveness of PRP, further anticipates its adoption rate in the medial practice. Therefore, the advantages provided by the use of PRP in the treatment of orthopedic and other related cases is further cementing its position as a pivotal therapy in regenerative medicine in the United States.
With increasing investments in healthcare, advanced technological changes in PRP therapies, and an increasingly aged population suffering from different chronic diseases, the platelet rich plasma market is on its boomers in China. Improving disposable incomes allow more people to afford advanced treatments like platelet rich plasma.
The therapy has proved its efficacy in the orthopedic segment, dermatological segment, and wound healing which embeds well within the Chinese healthcare landscape. Along with this growing awareness among patients about the added advantages of platelet rich plasma therapy, supported by its clinical evidence for its effectiveness further expands its growth in the Chinese market.
Therefore, the developing healthcare infrastructure, rising demand for advanced therapies, are some of the factors underline PRP's huge growth potential in China and make it one of the key players in the evolving healthcare industry of the country.
The section contains information about the leading segments in the industry. By product, the pure platelet-rich fibrin (P-PRF) segment is estimated to account for 42.1% of the market share and is anticipated to witness significant growth during the forecast period.
| Product | Value Share (2034) |
|---|---|
| Pure Platelet-rich Fibrin (P-PRF) | 42.1% |
The pure platelet-rich fibrin (P-PRF) segment dominates the market in terms of revenue, accounting for almost 42.1% of the market share in 2024. The segment dominates the market owing to its advanced therapeutic benefits such as its ability to release growth factors, which aid in tissue regeneration. The factor that pure platelet-rich fibrin doesn’t have anti-coagulants and other additives which differentiates it from the traditional platelet rich plasma and aid them to create scaffold that supports cell migration and tissue regeneration.
Other factors that have contributed to its significant growth is its superior clinical outcomes as compared to the traditional ones. Therefore, the segment has witnessed significant growth owing to it potential of improving wound healing process, tissue regeneration and bone growth. Additionally, the preferential shift of patients towards minimally invasive procedures, patient-derived treatments, its cost effective nature further drives its market growth and propels its market adoption.
| Origin Type | Value Share (2034) |
|---|---|
| Autologous Platelet-rich Plasma | 86.2% |
The autologous platelet-rich plasma segment is forecast to account for a revenue share of over 86.2% in the platelet rich plasma cover market by 2034 end. Factors that are favoring the growth of the segment is its ability to eliminate the risk of tissue infection, as it involves patients own biological material.
These factor accelerates the process of wound healing and makes it one of the appealing option among healthcare providers working in orthopedic, dermatology and dentistry field. Moreover, it’s the inclusion of higher concentrated growth factors makes it more effective in promoting tissue healing and regeneration process.
Its increasing availability in the point-of-care devices that have ability to process autologous platelet rich plasma efficiently in clinical settings, has contributed to its increased adoption. This combined clinical benefits, and its safety profile further surges the segment growth in the market.
Key players operating in the platelet rich plasma cover market are investing in development of advanced and innovative products that are more reliable and efficient. Also, many of the key players are emphasizing on making strategic collaborations and acquisition for expansion of their geographical presence and strengthening their market share.
Recent Industry Developments in Platelet Rich Plasma Market:
In terms of product type, the industry is divided into pure-platelet-rich plasma (P-PRP), leukocyte-platelet-rich plasma (L-PRP) and leukocyte-platelet-rich fibrin (L-PRF).
In terms of origin, the industry is divided into autologous, homologous and allogenic.
In terms of application, the industry is segregated into orthopedic surgery, cosmetic surgery, general surgery, neurosurgery and other surgeries
Key countries of North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and Middle East and Africa (MEA), have been covered in the report.
The global platelet rich plasma cover industry is projected to witness CAGR of 10.1% between 2024 and 2034.
The global platelet rich plasma cover industry stood at USD 444.4 million in 2024.
The global platelet rich plasma cover industry is anticipated to reach USD 1,163.1 million by 2034 end.
India is set to record the highest CAGR of 11.4% in the assessment period.
The key players operating in the global platelet rich plasma cover industry include Harvest Technologies Corp., Zimmer Biomet Holdings Inc., Arthrex, Inc., Arteriocyte Medical Systems, Inc. and Dr. PRP America are few of the key players in the platelet rich plasma cover industry
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Product 5.2. By Origin 5.3. By Application 5.4. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 6.1. Pure-Platelet-rich Plasma (P-PRP) 6.2. Leukocyte-Platelet-rich Plasma (L-PRP) 6.3. Leukocyte-Platelet-rich Fibrin (L-PRF) 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Origin 7.1. Autologous 7.2. Homologous 7.3. Allogenic 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 8.1. Orthopedic Surgery 8.2. Cosmetic Surgery 8.3. General Surgery 8.4. Neurosurgery 8.5. Other Surgeries (Urological, Cardiothoracic, Periodontal, and Oral and Maxillofacial) 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 9.1. North America 9.2. Latin America 9.3. East Asia 9.4. South Asia and Pacific 9.5. Western Europe 9.6. Eastern Europe 9.7. Middle East and Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Product, Origin, and Application for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Harvest Technologies Corp. 19.2. Zimmer Biomet Holdings Inc. 19.3. Arthrex, Inc. 19.4. Arteriocyte Medical Systems, Inc. 19.5. Dr. PRP America 19.6. Cesca Therapeutics, Inc. 19.7. Regen Lab SA. 19.8. Johnson & Johnson Services, Inc. 19.9. Stryker 19.10. Apex Biologix
Explore Healthcare Insights
View Reports
Platelet Rich Plasma Market
